A phase I trial of imetelstat in children with refractory or recurrent solid tumors: A children's oncology group phase I consortium study (ADVL1112)

Clinical Cancer Research

Volumn 19, Issue 23, 2013, Pages 6578-6584

  Thompson, Patrick A ^a   Drissi, Rachid ^b   Muscal, Jodi A ^a   Panditharatna, Eshini ^b   Fouladi, Maryam ^b   Ingle, Ashish M ^c   Ahern, Charlotte H ^a   Reid, Joel M ^e   Lin, Tong ^d   Weigel, Brenda J ^f   Blaney, Susan M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d GERON CORPORATION   (United States)

^e MAYO CLINIC   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMETELSTAT;

ADOLESCENT; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CATHETER INFECTION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RESPONSE; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OSTEOSARCOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REFRACTORY SOLID TUMOR; SCHOOL CHILD; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INDOLES; LEUKOCYTES, MONONUCLEAR; MALE; NEOPLASM RECURRENCE, LOCAL; NEUROBLASTOMA; NIACINAMIDE; SARCOMA, EWING; TELOMERASE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84890293036     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1117     Document Type: Article

References (24)

1. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-60.
2. Harley CB. Telomerase is not an oncogene. Oncogene 2002;21:494-502.
3. Blackburn EH. Structure and function of telomeres. Nature 1991;350:569-73.
4. Bosoy D, Peng Y, Mian IS, Lue NF. Conserved N-terminal motifs of telomerase reverse transcriptase required for ribonucleoprotein assembly in vivo. J Biol Chem 2003;278:3882-90.
5. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269:1236-41.
6. Counter CM, Avilion AA, Le Feuvre CE, Stewart NG, Greider CW, Harley CB, et al. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J 1992;11:1921-9.
7. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011-5.
8. Lichtsteiner SP, Lebkowski JS, Vasserot AP. Telomerase. A target for anticancer therapy. Ann N Y Acad Sci 1999;886:1-11.
9. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
10. Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, et al. Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol 1997;8:1063-74.
11. Tabori U, Dome JS. Telomere biology of pediatric cancer. Cancer Invest 2007;25:197-208.
12. Kim HR, Christensen R, Park NH, Sapp P, Kang MK. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res 2001;7:3079-86.
13. Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM, Chen CL. Telomerase activity in peripheral blood for diagnosis of hepatoma. J Gastroenterol Hepatol 2000;15:1064-70.
14. Watanabe M, Yu SK, Sawafuji M, Kawamura M, Horinouchi H, Mukai M, et al. Enhanced expression of telomerase activity in thymoma and thymic carcinoma tissues: a clinicopathologic study. Cancer 2002;94:240-4.
15. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005;65:7866-73.
16. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, et al. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 2006;12:3184-92.
17. Wang ES, Wu K, Chin AC, Chen-Kiang S, Pongracz K, Gryaznov S, et al. Telomerase inhibition with an oligonucleotide telomerase template antagonist: in vitro and in vivo studies in multiple myeloma and lymphoma. Blood 2004;103:258-66.
18. Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene 2002;21:656-63.
19. Didiano D, Shalaby T, Lang D, Grotzer MA. Telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro Oncol 2004;6:1-8.
20. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, et al. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010;16:154-63.
21. Williams SC. No end in sight for telomerase-targeted cancer drugs. Nat Med 2013;19:6.
22. Layne H. Personal communication: preclinical and clinical data for Imetelstat GRN163L. Menlo Park, CA: Geron Corporation; 2012.
23. Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC. Shortening the timeline of pediatric phase I trials:the rolling-six design. J Clin Oncol 2008;26:190-5.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.